so not all agreements are created equal... one key distinction I made about recent licensing deals are distribution vs license exclusivities, whereby the latter is holds no IP rights and is likely lower margin and the sponsor in this case Incyte can easily dis-intermediate knight medium-term once Knight builds Incyte's products in Brazil... does anyone know how long these agreements are for? and do you view certain deals as worth less than others?
- Entered into exclusive Distribution Agreement with Incyte for tafasitamab and pemigatinib
- Entered into exclusive license, distribution and supply agreement with Helsinn Healthcare SA for Akynzeo® oral/IV and Aloxi® oral/IV
- Entered into exclusive license and supply agreement with Rigel Pharmaceuticals for fostamatinib in Latin America